Trial Profile
Phase II Trial of RAD001 Plus Carboplatin in Patients With Triple-Negative Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Everolimus (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Apr 2013 Planned end date changed from 1 May 2015 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 16 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.